Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5984731 | 0.85 | CA1 (0.34) | CA1CA2CA9CA7CA13 | |
| SCHEMBL28139904 | 0.80 | CA1 (0.34) | CA1CA2CA9CA7CA13 | |
| SCHEMBL775774 | 0.78 | CA1 (0.35) | CA1CA2CA9CA7CA13 | |
| SCHEMBL8884453 | 0.77 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL21178830 | 0.75 | CA1 (0.33) | CA1CA2CA9 | |
| SCHEMBL25290646 | 0.75 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL29225513 | 0.75 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL18807459 | 0.75 | CA2 (0.39) | CA1CA2CA9 | |
| SCHEMBL14819931 | 0.75 | CA1 (0.36) | CA1CA2CA9CA7CA13 | |
| SCHEMBL778307 | 0.74 | CA1 (0.32) | CA1CA2CA9CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 554 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977848-A | Preparation of trifluoromethyl method for preparing trifluoroethyl sulfonate | 中船(邯郸)派瑞特种气体股份有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119855815-A | KRAS mutant protein inhibitor, and preparation method and application thereof | 甘李药业股份有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119462437-A | Trifluoromethanesulfonic acid three preparation method of fluoroethyl ester | 中船(邯郸)派瑞特种气体股份有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119431222-A | Method for asymmetrically synthesizing chiral intermediate of ubenimpam | 杭州澳赛诺生物科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| WO-2024061333-A1 | KRAS MUTANT PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 甘李药业股份有限公司 | 2024-03-28 | — | — | WO | claimed |
| CN-117105824-A | Preparation method of trifluoroethyl triflate | 衢州市九洲化工有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-113506868-B | Nonmetal-doped hard carbon negative electrode material and preparation method thereof | 山东玉皇新能源科技有限公司 | 2023-06-30 | — | — | CN | claimed |
| CN-113506868-A | Nonmetal-doped hard carbon negative electrode material and preparation method thereof | 山东玉皇新能源科技有限公司 | 2021-10-15 | — | — | CN | claimed |
| CN-109748831-A | A kind of preparation method of trifluoromethanesulfonic acid trifluoro ethyl ester | 南通正达农化有限公司 | 2019-05-14 | — | — | CN | claimed |
| CN-105633462-B | A kind of electrolyte containing fluorine-containing sulfurous esters compound and contain the lithium rechargeable battery of the electrolyte | 东莞市凯欣电池材料有限公司 | 2018-07-20 | — | — | CN | claimed |
| CN-105633462-A | Electrolyte containing fluorine-containing sulfite compound and lithium ion secondary battery containing electrolyte | DONGUAN KAIXIN BATTERY MAT CO LTD | 2016-06-01 | — | — | CN | claimed |
| CN-102942449-B | Synthetic method of 2,2-bis (trifluoroethyl) propanol | WUXI APPTEC CO LTD | 2015-01-07 | — | — | CN | claimed |
| CN-102627712-B | Preparation method and application of Ziegler Natta catalyst for propylene polymerization | CHANGCHUN APPLIED CHEMISTRY | 2014-02-12 | — | — | CN | claimed |
| CN-102617763-B | Preparation method of ultrahigh molecular weight polyethylene | CHANGCHUN APPLIED CHEMISTRY | 2014-02-12 | — | — | CN | claimed |
| CN-102627708-B | Preparation method for high-activity Ziegler Natta catalyst and application thereof | CHANGCHUN APPLIED CHEMISTRY | 2014-02-12 | — | — | CN | claimed |
| CN-102942449-A | Synthetic method of 2,2-bis (trifluoroethyl) propanol | WUXI APPTEC CO LTD | 2013-02-27 | — | — | CN | claimed |
| CN-102627712-A | Preparation method and application of Ziegler Natta catalyst for propylene polymerization | CHANGCHUN APPLIED CHEMISTRY | 2012-08-08 | — | — | CN | claimed |
| CN-102627708-A | Preparation method for high-activity Ziegler Natta catalyst and application thereof | CHANGCHUN APPLIED CHEMISTRY | 2012-08-08 | — | — | CN | claimed |
| CN-102617763-A | Preparation method of ultrahigh molecular weight polyethylene | CHANGCHUN APPLIED CHEMISTRY | 2012-08-01 | — | — | CN | claimed |
| CN-122071439-A | Benzo-ring-containing compounds as protein tyrosine phosphatase inhibitors and uses thereof | 湖北生物医药产业技术研究院有限公司 | 2026-05-22 | — | — | CN | disclosed |
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4740948-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 1,3-BENZODIOXOLE DERIVATIVE COMPOUND | Dong Wha Pharm. Co., Ltd. (KR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4741380-A1 | ISOXAZOLINE COMPOUND AND USE | NANJING PETMEDICINE TECHNOLOGY CO., LTD. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-12622917-B2 | High-activity Wnt pathway inhibitor compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| CN-122010767-A | Haloalkyl bisamide compound and application thereof | 山东熙霖生物科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4737458-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12570652-B2 | Pyrrolidine compound and use thereof | SIMCERE PHARMACEUTICAL CO., LTD. (CN) | 2026-03-10 | — | — | US | disclosed |
| US-12565481-B2 | 6,7-dimethoxy-3-(pyridin-2-yl)quinoline compounds for inhibiting RET | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2026-03-03 | — | — | US | disclosed |
| US-12552796-B2 | EED inhibitor, and preparation method therefor and use thereof | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| EP-4692090-A1 | TRICYCLIC COMPOUND AS ATR KINASE INHIBITOR | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| EP-4056570-B1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-01-07 | — | — | EP | disclosed |
| EP-4089082-B1 | QUINOLINE COMPOUNDS | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO LTD BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4638420-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | Exelixis, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-119462437-B | Trifluoromethanesulfonic acid three preparation method of fluoroethyl ester | 中船(邯郸)派瑞特种气体股份有限公司 | 2025-10-10 | — | — | CN | disclosed |
| WO-2025151549-A1 | PYRIDO[3,2-B]INDOLE-3-CARBONITRILE COMPOUNDS AND COMPOSITION FOR TARGETING TP53-Y220C MUTANTS | FLARE THERAPEUTICS INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025151478-A1 | COMPOUNDS AND COMPOSITION FOR TARGETING TP53-Y220C MUTANTS | FLARE THERAPEUTICS INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| CN-120202201-A | Inhibitors of ubiquitin-specific protease 1 and uses thereof | 深圳晶泰科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4570793-A1 | 5-HT2A RECEPTOR INVERSE AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Luye Innomind Pharma Shijiazhuang Co., Ltd. (CN) | 2025-06-18 | — | — | EP | disclosed |
| CN-115836068-B | Pyrrolidine compound and application thereof | 南京再明医药有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-120077047-A | Macrocyclic compound and medical application thereof | 正大天晴药业集团股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4559917-A1 | COMPOUND FOR RECOVERING P53 MUTATION FUNCTION AND USE THEREOF | Shenzhen Zhongge Biological Technology Co., Ltd. (CN) | 2025-05-28 | — | — | EP | disclosed |
| US-20250152588-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2025-05-15 | — | — | US | disclosed |
| CN-119977848-A | Preparation of trifluoromethyl method for preparing trifluoroethyl sulfonate | 中船(邯郸)派瑞特种气体股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119977848-A | Preparation of trifluoromethyl method for preparing trifluoroethyl sulfonate | 中船(邯郸)派瑞特种气体股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119977995-A | Macrocyclic derivatives and their use | 广州嘉越医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250136581-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| EP-4540254-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119855815-A | KRAS mutant protein inhibitor, and preparation method and application thereof | 甘李药业股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| WO-2025055856-A1 | P53-Y220C-SELECTIVE SMALL-MOLECULE REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 长春金赛药业有限责任公司 | 2025-03-20 | — | — | WO | disclosed |
| WO-2025056068-A1 | BICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海济煜医药科技有限公司 | 2025-03-20 | — | — | WO | disclosed |
| CN-119630650-A | 5-HT2AReceptor inverse agonist, preparation method and application thereof | 绿叶嘉奥制药石家庄有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119585275-A | Compound for restoring p53 mutation function and application thereof | 深圳众格生物科技有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-115703765-B | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119522225-A | Macrocyclic derivatives and their use | 广州嘉越医药科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20250059180-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2025-02-20 | — | — | US | disclosed |
| CN-119462437-A | Trifluoromethanesulfonic acid three preparation method of fluoroethyl ester | 中船(邯郸)派瑞特种气体股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119462437-A | Trifluoromethanesulfonic acid three preparation method of fluoroethyl ester | 中船(邯郸)派瑞特种气体股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119431316-A | Spiro compound, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119431222-A | Method for asymmetrically synthesizing chiral intermediate of ubenimpam | 杭州澳赛诺生物科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119350134-A | Method for recycling fluorine-containing waste gas in hexafluoropropylene oxide production and co-producing hydrofluoroether | 金华永和氟化工有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119345899-A | Production system for recycling fluorine-containing waste gas in production of hexafluoropropylene oxide and co-producing hydrofluoroether | 金华永和氟化工有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119306683-A | 10H-phenoxazine iron death inhibitor and preparation method and application thereof | 成都地奥九泓制药厂 | 2025-01-14 | — | — | CN | disclosed |
| WO-2025008783-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 1,3-BENZODIOXOLE DERIVATIVE COMPOUND | 동화약품주식회사 | 2025-01-09 | — | — | WO | disclosed |
| CN-116462687-B | WEE1 inhibitor and preparation and application thereof | 江苏天士力帝益药业有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024254990-A1 | COMPOUND HAVING HETEROAROMATIC RING STRUCTURE, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海璎黎药业有限公司 | 2024-12-19 | — | — | WO | disclosed |
| CN-119143747-A | Heteroaromatic ring structure compound, pharmaceutical composition and application thereof | 上海璎黎药业有限公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-4464701-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| US-20240368123-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| WO-2024208177-A1 | TRICYCLIC COMPOUND AS ATR KINASE INHIBITOR | 上海复星医药（集团）股份有限公司 | 2024-10-10 | — | — | WO | disclosed |
| CN-118652256-A | EED inhibitor and preparation method and application thereof | 上海科技大学 | 2024-09-17 | — | — | CN | disclosed |
| EP-4426729-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| CN-107973783-B | Alternylpyrimidine derivatives as ERK inhibitors | 正大天晴药业集团股份有限公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-118541367-A | 1, 3-Benzodioxole derivative compound and pharmaceutical composition containing same | 同和药品株式会社 | 2024-08-23 | — | — | CN | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240228446-A1 | PREPARATION METHOD FOR BICYCLIC COMPOUND AND APPLICATION AS ANTIFUNGAL AGENT | SHANGHAI JEMINCARE PHARMACEUTICAL CO., LTD (CN) | 2024-07-11 | — | — | US | disclosed |
| EP-4393920-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024137671-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | EXELIXIS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-118251392-A | Salt and crystal form of pyrrolidine compound and preparation method thereof | 南京再明医药有限公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4385988-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118126041-A | Tetracyclic compound and application thereof | 深圳众格生物科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118119620-A | Pharmaceutical composition for treating tumors and application thereof | 南京再明医药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118063393-A | 2, 4-Diaminopyrimidine derivative and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-05-24 | — | — | CN | disclosed |
| US-20240166610-A1 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | MEDSHINE DISCOVERY INC. (CN) | 2024-05-23 | — | — | US | disclosed |
| WO-2024094170-A1 | INHIBITOR OF UBIQUITIN-SPECIFIC PROTEASE 1 AND USE THEREOF | 深圳晶泰科技有限公司 | 2024-05-10 | — | — | WO | disclosed |
| WO-2024083223-A1 | MACROCYCLIC COMPOUNDS AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-117903123-A | Quinoline compounds | 广州白云山医药集团股份有限公司白云山制药总厂 | 2024-04-19 | — | — | CN | disclosed |
| CN-114929707-B | EED inhibitor and preparation method and application thereof | 上海科技大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117836294-A | Biological antagonist containing aromatic ring, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024067857-A1 | MACROCYCLIC DERIVATIVE AND USE THEREOF | 南京明德新药研发有限公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024061333-A1 | KRAS MUTANT PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 甘李药业股份有限公司 | 2024-03-28 | — | — | WO | disclosed |
| CN-115667275-B | Boron-containing compounds and uses thereof | 南京再明医药有限公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2024027800-A1 | 5-HT2A RECEPTOR INVERSE AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 嘉奥制药（石家庄）有限公司 | 2024-02-08 | — | — | WO | disclosed |
| EP-4317139-A1 | PREPARATION METHOD FOR BICYCLIC COMPOUND AND APPLICATION AS ANTIFUNGAL AGENT | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| CN-112538072-B | Aminopyrimidine EGFR inhibitors | 齐鲁制药有限公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2024017384-A1 | COMPOUND FOR RECOVERING P53 MUTATION FUNCTION AND USE THEREOF | 深圳众格生物科技有限公司 | 2024-01-25 | — | — | WO | disclosed |
| CN-113816969-B | Eptification control compound, antibody drug conjugate thereof and application thereof | 联宁（苏州）生物制药有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-115210226-B | Quinoline compounds | 广州白云山医药集团股份有限公司白云山制药总厂 | 2024-01-09 | — | — | CN | disclosed |
| WO-2023246870-A1 | PREPARATION, APPLICATION AND USE OF INDOLE COMPOUND | 上海济煜医药科技有限公司 | 2023-12-28 | — | — | WO | disclosed |
| CN-117279923-A | Derivative of six-membered heteroaromatic urea ring and application thereof | 南京明德新药研发有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023244604-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-4289823-A1 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | Medshine Discovery Inc. (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230390301-A1 | HIGH-ACTIVITY WNT PATHWAY INHIBITOR COMPOUND | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2023-12-07 | — | — | US | disclosed |
| CN-117157279-A | Preparation method of bicyclo compound and application of bicyclo compound as antibacterial agent | 上海济煜医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-115403565-B | Pyrimidine or pyridine compound, preparation method and medical application thereof | 益方生物科技(上海)股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-117105824-A | Preparation method of trifluoroethyl triflate | 衢州市九洲化工有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117105824-A | Preparation method of trifluoroethyl triflate | 衢州市九洲化工有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117105824-A | Preparation method of trifluoroethyl triflate | 衢州市九洲化工有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-11814371-B2 | Heterocyclic compound | MEDSHINE DISCOVERY INC. (CN) | 2023-11-14 | — | — | US | disclosed |
| CN-111196804-B | TGF-beta R1 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230348459-A1 | PYRROLIDINE COMPOUND AND USE THEREOF | SIMCERE PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2023198172-A1 | OXADIAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 勤浩医药（苏州）有限公司 | 2023-10-19 | — | — | WO | disclosed |
| CN-116867769-A | Substituted pyridazine phenol derivatives | 南京明德新药研发有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-20230312504-A1 | QUINOLINE COMPOUNDS | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2023-10-05 | — | — | US | disclosed |
| CN-116806250-A | Fluorine substituted asymmetric ethers, compositions, methods and uses comprising the same | 霍尼韦尔国际公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116731031-A | Down-praline derivative and application thereof | 贵州药法自然医药科技有限公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2023165523-A1 | AROMATIC RING-SUBSTITUTED METHOXY DERIVATIVE AND USE THEREOF | 上海璎黎药业有限公司 | 2023-09-07 | — | — | WO | disclosed |
| EP-4238974-A1 | HIGH-ACTIVITY WNT PATHWAY INHIBITOR COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| CN-116693514-A | Aromatic ring substituted methoxy derivative and application thereof | 上海璎黎药业有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-111655678-B | Apoptosis signal regulating kinase-1 inhibitor and application thereof | 广州市恒诺康医药科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11731966-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4219461-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | Medshine Discovery Inc. (CN) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023138362-A1 | WEE1 INHIBITOR, PREPARATION THEREFOR, AND USE THEREOF | 江苏天士力帝益药业有限公司 | 2023-07-27 | — | — | WO | disclosed |
| CN-116462687-A | WEE1 inhibitor and preparation and application thereof | 江苏天士力帝益药业有限公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2023135564-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 동화약품주식회사 | 2023-07-20 | — | — | WO | disclosed |
| CN-113506868-B | Nonmetal-doped hard carbon negative electrode material and preparation method thereof | 山东玉皇新能源科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116348455-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116348469-A | High-activity Wnt pathway inhibitor compound | 杭州阿诺生物医药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230167098-A1 | HETEROCYCLIC COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| CN-107548391-B | Pyrimidine or pyridine compound, preparation method and medical application thereof | 益方生物科技(上海)股份有限公司 | 2023-05-26 | — | — | CN | disclosed |
| WO-2023083283-A1 | DRUG COMBINATION FOR TREATING TUMOR, AND APPLICATION THEREOF | 先声药业有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083292-A1 | SALT OF PYRROLIDINE COMPOUND, CRYSTAL FORM THEREOF, AND PREPARATION METHOD THEREFOR | 先声药业有限公司 | 2023-05-19 | — | — | WO | disclosed |
| CN-116134034-A | Tetrahydroisoquinoline derivative and application thereof | 南京明德新药研发有限公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2023078273-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | disclosed |
| CN-111170998-B | Pyrimidine or pyridine compound, preparation method and medical application thereof | 益方生物科技(上海)股份有限公司 | 2023-04-11 | — | — | CN | disclosed |
| EP-4151636-A1 | PYRROLIDINE COMPOUND AND USE THEREOF | Simcere Pharmaceutical Co. Ltd. (CN) | 2023-03-22 | — | — | EP | disclosed |
| CN-115836068-A | Pyrrolidine compounds and application thereof | 先声药业有限公司 | 2023-03-21 | — | — | CN | disclosed |
| WO-2023025277-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-03-02 | — | — | WO | disclosed |
| CN-115703765-A | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-112920199-B | Piperazinone substituent or derivative thereof, preparation method and application thereof, and pharmaceutical composition | 四川大学 | 2023-02-03 | — | — | CN | disclosed |
| CN-115677684-A | Substituted aryl or heteroaryl compounds | 先声药业有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115667275-A | Boron-containing compounds and their use | 先声药业有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230019236-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2023-01-19 | — | — | US | disclosed |
| CN-115611924-A | PD-1/PD-L1 inhibitor and preparation method and application thereof | 上海华汇拓医药科技有限公司 | 2023-01-17 | — | — | CN | disclosed |
| EP-4116299-A1 | HETEROCYCLIC COMPOUND | Medshine Discovery Inc. (CN) | 2023-01-11 | — | — | EP | disclosed |
| CN-110382499-B | FGFR inhibitor and application thereof | 贝达药业股份有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115403565-A | Pyrimidine or pyridine compound, preparation method and medical application thereof | 益方生物科技(上海)股份有限公司 | 2022-11-29 | — | — | CN | disclosed |
| EP-4089082-A1 | QUINOLINE COMPOUNDS | Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory (CN) | 2022-11-16 | — | — | EP | disclosed |
| US-11498921-B1 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | InventisBio Co., Ltd. (CN) | 2022-11-15 | — | — | US | disclosed |
| WO-2022228365-A1 | DERIVATIVE OF SIX-MEMBERED HETEROAROMATIC UREA RING AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2022-11-03 | — | — | WO | disclosed |
| CN-108276382-B | Cyclin-dependent kinase inhibitor and application thereof | 南京圣和药物研发有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-115210230-A | Heterocyclic compounds | 南京明德新药研发有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-115210226-A | Quinoline compound | 广州白云山医药集团股份有限公司白云山制药总厂 | 2022-10-18 | — | — | CN | disclosed |
| WO-2022206862-A1 | PREPARATION METHOD FOR BICYCLIC COMPOUND AND APPLICATION AS ANTIFUNGAL AGENT | 上海济煜医药科技有限公司 | 2022-10-06 | — | — | WO | disclosed |
| CN-113278013-B | 2, 6-disubstituted 1,2, 4-triazine-3, 5-diketone compound and preparation method and application thereof | 昆药集团股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-110054618-B | Pyrimidine or pyridine compound, preparation method and medical application thereof | 益方生物科技(上海)股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-110483366-B | Indole compound and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-09-16 | — | — | CN | disclosed |
| EP-4056570-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ShanghaiTech University (CN) | 2022-09-14 | — | — | EP | disclosed |
| CN-114929707-A | EED inhibitor and preparation method and application thereof | 上海科技大学 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022166890-A1 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | 南京明德新药研发有限公司 | 2022-08-11 | — | — | WO | disclosed |
| US-20220226326-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-07-21 | — | — | US | disclosed |
| CN-114656464-A | 6,7,8, 9-tetrahydro-3H-pyrazolo [4,3-f ] isoquinoline derivatives useful for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| WO-2022089454-A1 | HIGH-ACTIVITY WNT PATHWAY INHIBITOR COMPOUND | 杭州阿诺生物医药科技有限公司 | 2022-05-05 | — | — | WO | disclosed |
| WO-2022063094-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | 南京明德新药研发有限公司 | 2022-03-31 | — | — | WO | disclosed |
| CN-113816969-A | Irinotecan compound, antibody drug conjugate thereof and application thereof | 联宁（苏州）生物制药有限公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-108137562-B | Pyrazolopyrimidine derivative and use thereof | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20210355118-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-11-18 | — | — | US | disclosed |
| WO-2021213358-A1 | BORON-CONTAINING COMPOUNDS AND APPLICATION THEREOF | 江苏先声药业有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| CN-113506868-A | Nonmetal-doped hard carbon negative electrode material and preparation method thereof | 山东玉皇新能源科技有限公司 | 2021-10-15 | — | — | CN | disclosed |
| CN-113278013-A | 2, 6-disubstituted 1,2, 4-triazine-3, 5-diketone compound and preparation method and application thereof | 昆药集团股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| US-11084829-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| WO-2021127499-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| CN-112955438-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-112920199-A | Piperazinone substituent or derivative thereof, and preparation method, application and pharmaceutical composition thereof | 四川大学 | 2021-06-08 | — | — | CN | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| WO-2021083380-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2021-05-06 | — | — | WO | disclosed |
| EP-3810580-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10954202-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | ABBVIE INC. (US) | 2021-03-23 | — | — | US | disclosed |
| CN-112538072-A | Novel aminopyrimidine EGFR (epidermal growth factor receptor) inhibitor | 齐鲁制药有限公司 | 2021-03-23 | — | — | CN | disclosed |
| CN-108329246-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors | 阵列生物制药公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20210009542-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2021-01-14 | — | — | US | disclosed |
| CN-106588890-B | Antiviral compounds | 吉利德制药有限责任公司 | 2020-11-27 | — | — | CN | disclosed |
| US-20200345735-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-11-05 | — | — | US | disclosed |
| CN-105985354-B | Pyrimidine derivatives, cytotoxic agents, pharmaceutical compositions and uses thereof | 南京盖特医药技术有限公司 | 2020-10-02 | — | — | CN | disclosed |
| CN-111655678-A | Apoptosis signal-regulating kinase-1 inhibitor and application thereof | 广州市恒诺康医药科技有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-107207466-B | Bicyclic compounds as pest control agents | 拜耳作物科学股份公司 | 2020-09-08 | — | — | CN | disclosed |
| CN-111196804-A | TGF- β R1 inhibitor and application thereof | 南京圣和药业股份有限公司 | 2020-05-26 | — | — | CN | disclosed |
| CN-111170998-A | Pyrimidine or pyridine compound, preparation method and medical application thereof | 益方生物科技（上海）有限公司 | 2020-05-19 | — | — | CN | disclosed |
| EP-2849568-B1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2020068600-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20200095260-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2020-03-26 | — | — | US | disclosed |
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| WO-2020054670-A1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | 科研製薬株式会社 | 2020-03-19 | — | — | WO | disclosed |
| CN-110483366-A | Benzazole compounds and preparation method thereof, pharmaceutical composition and purposes | INST MATERIA MEDICA CAMS | 2019-11-22 | — | — | CN | disclosed |
| CN-110483485-A | Pyrimidines, preparation method and medical usage | INVENTISBIO SHANGHAI CO LTD | 2019-11-22 | — | — | CN | disclosed |
| EP-3233858-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| CN-110382499-A | FGFR inhibitor and its application | 贝达药业股份有限公司 | 2019-10-25 | — | — | CN | disclosed |
| US-20190297887-A1 | BICYCLIC COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-10-03 | — | — | US | disclosed |
| CN-110054618-A | Pyrimidine or pyridine compounds and their, preparation method and medical usage | 益方生物科技（上海）有限公司 | 2019-07-26 | — | — | CN | disclosed |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-06-18 | — | — | US | disclosed |
| CN-109843888-A | 6, 7, 8, 9-tetrahydro-3H-pyrazolo [4, 3-f ] isoquinoline derivatives useful for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2019-06-04 | — | — | CN | disclosed |
| CN-109748831-A | A kind of preparation method of trifluoromethanesulfonic acid trifluoro ethyl ester | 南通正达农化有限公司 | 2019-05-14 | — | — | CN | disclosed |
| CN-109748831-A | A kind of preparation method of trifluoromethanesulfonic acid trifluoro ethyl ester | 南通正达农化有限公司 | 2019-05-14 | — | — | CN | disclosed |
| CN-109748831-A | A kind of preparation method of trifluoromethanesulfonic acid trifluoro ethyl ester | 南通正达农化有限公司 | 2019-05-14 | — | — | CN | disclosed |
| CN-105523873-B | The preparation method of fluorine-containing ternary cycle compound, preparation method and fluoroalkyl sulfonium salt | 中国科学院上海有机化学研究所 | 2019-03-15 | — | — | CN | disclosed |
| CN-109476646-A | Dicyclic compound as pest control agent | 拜耳作物科学股份公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-105085489-B | Pyrimidine or pyridine compound, preparation method and medical application thereof | 益方生物科技（上海）有限公司 | 2019-03-01 | — | — | CN | disclosed |
| EP-3442947-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | Epizyme Inc (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3430906-A1 | CRYSTALLINE FORMS OF CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2019-01-23 | — | — | EP | disclosed |
| CN-109020961-A | Antiviral compound | 吉利德制药有限责任公司 | 2018-12-18 | — | — | CN | disclosed |
| US-20180334450-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-10131649-B2 | Bicyclic compounds as pest control agents | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-11-20 | — | — | US | disclosed |
| CN-108727343-A | Quinazolinones PARP-1/2 inhibitor containing 3- amino nafoxidines and preparation method thereof, pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2018-11-02 | — | — | CN | disclosed |
| US-10106541-B2 | Intermediates for preparing CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-10-23 | — | — | US | disclosed |
| CN-104230900-B | Antiviral compound | 吉利德制药有限责任公司 | 2018-10-19 | — | — | CN | disclosed |
| CN-104418866-B | Dgat1 inhibitor and its preparation method and application | 青岛黄海制药有限责任公司 | 2018-10-16 | — | — | CN | disclosed |
| WO-2018187480-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-10-11 | — | — | WO | disclosed |
| WO-2018165520-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VPS-3, INC. (US) | 2018-09-13 | — | — | WO | disclosed |
| CN-108329246-A | Pyrrolidinyl urea and pyrrolidinyl thiourea compound as TRKA kinase inhibitors | 阵列生物制药公司 | 2018-07-27 | — | — | CN | disclosed |
| CN-105633462-B | A kind of electrolyte containing fluorine-containing sulfurous esters compound and contain the lithium rechargeable battery of the electrolyte | 东莞市凯欣电池材料有限公司 | 2018-07-20 | — | — | CN | disclosed |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180127417-A1 | INTERMEDIATES FOR PREPARING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-05-10 | — | — | US | disclosed |
| CN-107973783-A | Aniline pyrimidine derivative as ERK inhibitor | 正大天晴药业集团股份有限公司 | 2018-05-01 | — | — | CN | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| CN-105130967-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compound as TRKA kinase inhibitors | 阵列生物制药公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-105531277-B | Pyrrolo-imidazole ring derivatives and their use in medicine | 四川海思科制药有限公司 | 2018-03-02 | — | — | CN | disclosed |
| CN-103304571-B | Spiro-compound, its preparation method, intermediate, pharmaceutical composition and application | 凯惠科技发展(上海)有限公司 | 2018-02-16 | — | — | CN | disclosed |
| US-9884048-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9878997-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| CN-107548391-A | pyrimidine or pyridine compound, preparation method and medical application thereof | 上海页岩科技有限公司 | 2018-01-05 | — | — | CN | disclosed |
| US-9850246-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170327487-A1 | BICYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-11-16 | — | — | US | disclosed |
| EP-3233858-A1 | ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017181177-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2017-10-19 | — | — | WO | disclosed |
| CN-107207466-A | Bicyclic compounds as pest control agents | 拜耳作物科学股份公司 | 2017-09-26 | — | — | CN | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| CN-107148420-A | Benzyl substituted indazoles | 拜耳制药股份公司 | 2017-09-08 | — | — | CN | disclosed |
| US-9751888-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170217936-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-08-03 | — | — | US | disclosed |
| EP-3164395-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Novartis AG (CH) | 2017-05-10 | — | — | EP | disclosed |
| CN-106588890-A | Antiviral compounds | 吉利德制药有限责任公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-104211713-B | Antiviral compounds | 吉利德制药有限责任公司 | 2017-04-12 | — | — | CN | disclosed |
| CN-104168768-B | The method of preparation Cgrp receptor antagonist | 默沙东公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-106470985-A | Indane and indoline derivatives as soluble guanylate cyclase activators and uses thereof | 诺华股份有限公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-103517903-B | Pyrrolopyridine aminoderivative as MPS1 inhibitor | 癌症研究科技有限公司 | 2017-03-01 | — | — | CN | disclosed |
| US-9562055-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| CN-104211689-B | Antiviral compounds | 吉利德制药有限责任公司 | 2017-01-18 | — | — | CN | disclosed |
| EP-2712358-B1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9487523-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| CN-103977406-B | Antiviral compound | 吉利德制药有限责任公司 | 2016-10-19 | — | — | CN | disclosed |
| CN-105980363-A | Aminopyrazolone Derivatives | 第三共株式会社 | 2016-09-28 | — | — | CN | disclosed |
| EP-2401265-B1 | DERIVATIVES OF 1-PYRI(MID)IN-2-YL-PYRAZOLE-4-CARBOXYLIC ACID WHICH ARE USEFUL FOR THERAPY OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-3063144-A1 | ANTIPARISITIC AND PESTICIDAL ISOXAZOLINE COMPOUNDS | Merial, Inc. (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160222016-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160212997-A1 | AGRICULTURAL CHEMICALS | REDAG CROP PROT LTD (GB) | 2016-07-28 | — | — | US | disclosed |
| EP-3046418-A2 | AGRICULTURAL CHEMICALS | Redag Crop Protection Ltd (GB) | 2016-07-27 | — | — | EP | disclosed |
| WO-2016100050-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016095089-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| CN-105705022-A | Agricultural chemicals | 瑞戴格作物保护公司 | 2016-06-22 | — | — | CN | disclosed |
| US-9371319-B2 | Pyrrolopyridineamino derivatives as MPS1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-21 | — | — | US | disclosed |
| US-9359340-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2016-06-02 | — | — | US | disclosed |
| CN-105633462-A | Electrolyte containing fluorine-containing sulfite compound and lithium ion secondary battery containing electrolyte | DONGUAN KAIXIN BATTERY MAT CO LTD | 2016-06-01 | — | — | CN | disclosed |
| CN-104016971-B | Antiviral compound | PHARMASSET INC. (US) | 2016-05-25 | — | — | CN | disclosed |
| US-20160130273-A1 | Process for Making CGRP Receptor Antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-05-12 | — | — | US | disclosed |
| CN-105523873-A | Fluorine-containing three-membered ring compound, preparation method of fluorine-containing three-membered ring compound and preparation method of fluoroalkyl sulfonium salt | SHANGHAI INST ORGANIC CHEMISTRY CAS | 2016-04-27 | — | — | CN | disclosed |
| CN-105531277-A | Pyrrolo-imidazole ring derivatives and their use in medicine | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2016-04-27 | — | — | CN | disclosed |
| WO-2016055605-A1 | PESTICIDALLY ACTIVE BICYCLIC HETEROAROMATIC COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-04-14 | — | — | WO | disclosed |
| US-9309252-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2016-04-12 | — | — | US | disclosed |
| EP-3002281-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2686318-B1 | PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS | CANCER REC TECH LTD (GB) | 2016-03-09 | — | — | EP | disclosed |
| EP-2966065-A2 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| WO-2016001875-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2016-01-07 | — | — | WO | disclosed |
| CN-105130967-A | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors | ARRAY BIOPHARMA INC | 2015-12-09 | — | — | CN | disclosed |
| EP-2483277-B1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-12-02 | — | — | EP | disclosed |
| CN-102762574-B | Benzoxapi 3K inhibitor compounds and methods of use | HOFFMAN-LA ROCHE LTD. (CH) | 2015-12-02 | — | — | CN | disclosed |
| US-9198917-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-12-01 | — | — | US | disclosed |
| CN-105085489-A | Pyrimidine or pyridine compound, preparation method and medical application thereof | SHANGHAI YEYAN TECHNOLOGY CO LTD | 2015-11-25 | — | — | CN | disclosed |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. | 2015-11-12 | — | — | US | disclosed |
| US-9175009-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174989-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2931731-A1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS AS INHIBITORS OF BACE1 | Pfizer Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| CN-104987345-A | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE | 2015-10-21 | — | — | CN | disclosed |
| EP-2928867-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| CN-102958922-B | 2,5,6,7-tetrahydrochysene-[Isosorbide-5-Nitrae] oxygen azepine *-3-base amine or 2,3,6,7-tetrahydrochysene-[Isosorbide-5-Nitrae] oxygen azepine *-5-ylamine compounds | HOFFMAN-LA ROCHE LTD. (CH) | 2015-09-30 | — | — | CN | disclosed |
| CN-103649076-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-09 | — | — | CN | disclosed |
| EP-2399909-B1 | Hydroxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2402325-B1 | Hydroxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9115098-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150231144-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-08-20 | — | — | US | disclosed |
| CN-102918043-B | pyrrolopyrimidine compounds as CDK4/6 inhibitors | NOVARTIS AG (CH) | 2015-07-29 | — | — | CN | disclosed |
| EP-2536730-B1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2015-07-08 | — | — | EP | disclosed |
| US-20150166564-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | Array BioPharama Inc. (US) | 2015-06-18 | — | — | US | disclosed |
| US-9045498-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-06-02 | — | — | US | disclosed |
| WO-2015066277-A1 | ANTIPARISITIC AND PESTICIDAL ISOXAZOLINE COMPOUNDS | MERIAL LIMITED (US) | 2015-05-07 | — | — | WO | disclosed |
| US-20150112067-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-04-23 | — | — | US | disclosed |
| WO-2015051241-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2015-04-09 | — | — | US | disclosed |
| US-20150094347-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-04-02 | — | — | US | disclosed |
| WO-2015040408-A2 | AGRICULTURAL CHEMICALS | REDX PHARMA LIMITED (GB) | 2015-03-26 | — | — | WO | disclosed |
| EP-2849568-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2015-03-25 | — | — | EP | disclosed |
| CN-104418866-A | DGAT1 inhibitor, and preparation method and application thereof | NANJING MINGDE NEW DRUG RES AND DEV CO LTD | 2015-03-18 | — | — | CN | disclosed |
| US-8957074-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| US-8952043-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | GENETECH, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2825044-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| CN-102942449-B | Synthetic method of 2,2-bis (trifluoroethyl) propanol | WUXI APPTEC CO LTD | 2015-01-07 | — | — | CN | disclosed |
| CN-102942449-B | Synthetic method of 2,2-bis (trifluoroethyl) propanol | WUXI APPTEC CO LTD | 2015-01-07 | — | — | CN | disclosed |
| CN-104230900-A | Antiviral compounds | GILEAD SCIENCES INC | 2014-12-24 | — | — | CN | disclosed |
| CN-104211713-A | Antiviral compounds | GILEAD SCIENCES INC | 2014-12-17 | — | — | CN | disclosed |
| CN-104211689-A | Antiviral compounds | GILEAD SCIENCES INC | 2014-12-17 | — | — | CN | disclosed |
| US-20140349996-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349997-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-11-27 | — | — | US | disclosed |
| CN-104168768-A | Process for making cgrp receptor antagonists | MERCK SHARP | 2014-11-26 | — | — | CN | disclosed |
| US-20140323474-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER (US) | 2014-10-30 | — | — | US | disclosed |
| US-8853199-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2784078-A1 | Benzoxepin pi3k inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-8846681-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2646443-B1 | KAT II INHIBITORS | PFIZER (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8841278-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2014-09-04 | — | — | US | disclosed |
| CN-104016971-A | Antiviral compounds | GILEAD SCIENCES INC | 2014-09-03 | — | — | CN | disclosed |
| US-8822456-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822430-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-02 | — | — | US | disclosed |
| CN-103977406-A | Antiviral compounds | GILEAD SCIENCES INC | 2014-08-13 | — | — | CN | disclosed |
| WO-2014091352-A1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS AS INHIBITORS OF BACE1 | PFIZER INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140163015-A1 | HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER INC. (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2014086805-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| CN-102596936-B | Antiviral compounds | GILEAD SCIENCES INC | 2014-06-11 | — | — | CN | disclosed |
| US-20140135308-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| CN-103649076-A | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors | ARRAY BIOPHARMA INC | 2014-03-19 | — | — | CN | disclosed |
| US-8673948-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673952-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2014-03-18 | — | — | US | disclosed |
| US-8669234-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140051656-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| CN-102617763-B | Preparation method of ultrahigh molecular weight polyethylene | CHANGCHUN APPLIED CHEMISTRY | 2014-02-12 | — | — | CN | disclosed |
| CN-102627712-B | Preparation method and application of Ziegler Natta catalyst for propylene polymerization | CHANGCHUN APPLIED CHEMISTRY | 2014-02-12 | — | — | CN | disclosed |
| CN-102627708-B | Preparation method for high-activity Ziegler Natta catalyst and application thereof | CHANGCHUN APPLIED CHEMISTRY | 2014-02-12 | — | — | CN | disclosed |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| EP-2686318-A1 | PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS | Cancer Research Technology Ltd (GB) | 2014-01-22 | — | — | EP | disclosed |
| EP-2079466-B1 | SUBSTITUTED INDOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-01-15 | — | — | EP | disclosed |
| CN-103517903-A | Pyrrolopyridineamino derivatives as MPS1 inhibitors | CANCER REC TECH LTD | 2014-01-15 | — | — | CN | disclosed |
| CN-103502227-A | 1 as BACE1 and/or BACE2 inhibitors | HOFFMANN LA ROCHE | 2014-01-08 | — | — | CN | disclosed |
| EP-2678329-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20130345181-A1 | PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-12-26 | — | — | US | disclosed |
| US-8598200-B2 | KAT II inhibitors | PFIZER INC. (US) | 2013-12-03 | — | — | US | disclosed |
| WO-2013169348-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-8575118-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575150-B2 | Triazole derivatives for treatment of Alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2013-11-05 | — | — | US | disclosed |
| CN-102076658-B | Method for sulphonylation of hydroxylated organic compound | RHODIA OPERATIONS | 2013-10-30 | — | — | CN | disclosed |
| EP-2646443-A1 | KAT II INHIBITORS | Pfizer Inc (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2013138418-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | WO | disclosed |
| EP-2638042-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-09-18 | — | — | EP | disclosed |
| CN-103304571-A | Spiro compound as well as preparation method, intermediate, pharmaceutical composition and application thereof | SHANGHAI YUNYI HEALTH ADMINISTRATION CONSULTING CO LTD | 2013-09-18 | — | — | CN | disclosed |
| EP-2632551-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8507512-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130196984-A1 | 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2013-08-01 | — | — | US | disclosed |
| CN-103228660-A | Kat II inhibitors | PFIZER | 2013-07-31 | — | — | CN | disclosed |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| EP-2118102-B1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8399709-B2 | Method for the sulfonylation of a hydroxylated organic compound | RHODIA OPERATIONS (FR) | 2013-03-19 | — | — | US | disclosed |
| CN-102958922-A | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | HOFFMANN LA ROCHE | 2013-03-06 | — | — | CN | disclosed |
| CN-102942449-A | Synthetic method of 2,2-bis (trifluoroethyl) propanol | WUXI APPTEC CO LTD | 2013-02-27 | — | — | CN | disclosed |
| CN-102942449-A | Synthetic method of 2,2-bis (trifluoroethyl) propanol | WUXI APPTEC CO LTD | 2013-02-27 | — | — | CN | disclosed |
| CN-102918043-A | Pyrrolopyrimidine compounds as CDK4/6 inhibitors | NOVARTIS AG | 2013-02-06 | — | — | CN | disclosed |
| US-20130029978-A1 | NOVEL ARYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. | 2013-01-31 | — | — | US | disclosed |
| US-20130012488-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BLAQUIERE NICOLE (US) | 2013-01-10 | — | — | US | disclosed |
| EP-2536730-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | Novartis AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-20120302599-A1 | KAT ll INHIBITORS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| WO-2012158413-A2 | PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012154274-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| EP-2518064-A1 | NOVEL ARYL UREA DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| CN-102762574-A | Benzoxapi 3K inhibitor compounds and methods of use | HOFFMANN LA ROCHE | 2012-10-31 | — | — | CN | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| EP-2507236-A1 | TRIAZOLOPYRIDINE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| CN-102712609-A | 2-amino-5, 5-difluoro-5, 6-dihydro-4H-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN LA ROCHE | 2012-10-03 | — | — | CN | disclosed |
| CN-102712640-A | Tricyclic heterocyclic compounds, compositions and methods of use thereof | HOFFMANN LA ROCHE | 2012-10-03 | — | — | CN | disclosed |
| US-8273341-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| WO-2012123745-A1 | PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-09-20 | — | — | WO | disclosed |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8263633-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2012-09-11 | — | — | US | disclosed |
| CN-102652129-A | Amino oxazine derivatives | HOFFMANN LA ROCHE | 2012-08-29 | — | — | CN | disclosed |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | ANDREINI MATTEO (IT) | 2012-08-23 | — | — | US | disclosed |
| CN-102639516-A | 3-amino-5-phenyl-5, 6-dihydro-2H- [1,4] oxazine derivatives | HOFFMANN LA ROCHE | 2012-08-15 | — | — | CN | disclosed |
| US-8242150-B2 | Triazole derivatives for treating alzheimer'S disease and related conditions | MERCK SHARP & DOHME CORP. (US) | 2012-08-14 | — | — | US | disclosed |
| CN-102627712-A | Preparation method and application of Ziegler Natta catalyst for propylene polymerization | CHANGCHUN APPLIED CHEMISTRY | 2012-08-08 | — | — | CN | disclosed |
| CN-102627708-A | Preparation method for high-activity Ziegler Natta catalyst and application thereof | CHANGCHUN APPLIED CHEMISTRY | 2012-08-08 | — | — | CN | disclosed |
| CN-102617763-A | Preparation method of ultrahigh molecular weight polyethylene | CHANGCHUN APPLIED CHEMISTRY | 2012-08-01 | — | — | CN | disclosed |
| CN-102596936-A | Antiviral compounds | GILEAD SCIENCES INC | 2012-07-18 | — | — | CN | disclosed |
| CN-101516859-B | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives | HOFFMANN LA ROCHE | 2012-07-04 | — | — | CN | disclosed |
| US-8207180-B2 | Tricyclic indoles and (4,5-dihydro) indoles | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-26 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012073143-A1 | KAT II INHIBITORS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-8188079-B2 | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2012064910-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012058132-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| CN-102414194-A | Soluble guanylate cyclase activators | MERCK SHARP & DOHME | 2012-04-11 | — | — | CN | disclosed |
| EP-2430014-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
| EP-2401265-A2 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402325-A2 | Hydroxylated and methoxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | Array Biopharma, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2399909-A1 | Hydroxylated and methoxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors | Array Biopharma, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20110313001-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | FISCHER CHRISTIAN (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2378879-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2379075-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110237640-A1 | PYRAZOLE PHENYL DERIVATIVES | ACKERMANN JEAN | 2011-09-29 | — | — | US | disclosed |
| US-8026262-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2011-09-27 | — | — | US | disclosed |
| EP-2049501-B1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2049500-B1 | CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-09-07 | — | — | EP | disclosed |
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-8003651-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110190542-A1 | METHOD FOR THE SULFONYLATION OF A HYDROXYLATED ORGANIC COMPOUND | RHODIA OPERATIONS (FR) | 2011-08-04 | — | — | US | disclosed |
| WO-2011064328-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
| CN-102076658-A | Method for the sulphonylation of a hydroxylated organic compound | RHODIA OPERATIONS | 2011-05-25 | — | — | CN | disclosed |
| US-20110076291-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2011-02-24 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010099054-A2 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100222320-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | SCHERING CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-7763614-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-07-27 | — | — | US | disclosed |
| WO-2010077582-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010071741-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-06-24 | — | — | WO | disclosed |
| EP-2166854-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-03-25 | — | — | US | disclosed |
| EP-1805323-B1 | SYSTEMS AND METHODS FOR EVALUATING ENZYME COMPETENCY | UNIV FLORIDA (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20100035953-A1 | Pyrazole Phenyl Derivatives | ACKERMANN JEAN | 2010-02-11 | — | — | US | disclosed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2118102-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-18 | — | — | EP | disclosed |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| CN-101516859-A | 4-oxo-2, 3,4, 5-tetrahydro-benzo [b] [1,4] diaza derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | disclosed |
| US-7572820-B2 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| CN-101497566-A | Preparation of 2,5-bis(2,2,2-trifluoro ethoxy) benzene carbonic acid | Taicang Pharmaceutical Factory (CN) | 2009-08-05 | — | — | CN | disclosed |
| EP-2079466-A2 | SUBSTITUTED INDOLE COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1742923-B1 | PYRAZOLE PHENYL DERIVATIVES AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | EP | disclosed |
| EP-2049501-A1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2049500-A1 | CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| CN-100467463-C | Pyrazolylindolyl derivatives as PPAR activators | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | CN | disclosed |
| US-20090005270-A1 | Systems and Methods for Evaluating Enzyme Competency | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008156580-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1725546-B1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-7414049-B2 | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1667981-A4 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1937670-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT M1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-07-02 | — | — | EP | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008065054-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-05 | — | — | WO | disclosed |
| US-20080103133-A1 | 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[b][1,4]DIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008006040-A1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008006032-A1 | CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-7265149-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1805323-A2 | SYSTEMS AND METHODS FOR EVALUATING ENZYME COMPETENCY | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007036711-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| US-7196197-B2 | Process for the preparation of Flecainide, its pharmaceutically acceptable salts and important intermediates thereof | APOTEX PHARMACHEM INC. | 2007-03-27 | — | — | US | disclosed |
| CN-1930150-A | Pyrazolyl indolyl derivatives as PPAR activators | HOFFMANN LA ROCHE (CH) | 2007-03-14 | — | — | CN | disclosed |
| US-20070054892-A1 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-03-08 | — | — | US | disclosed |
| EP-1742923-A1 | PYRAZOLE PHENYL DERIVATIVES AS PPAR ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| EP-1725546-A1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| CN-1856477-A | Isoquinoline potassium channel inhibitors | MERCK & CO INC (US) | 2006-11-01 | — | — | CN | disclosed |
| EP-1667981-A1 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1659111-A2 | Piperidine derivatives useful as ccr5 antagonists | Schering Corporation (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2006034370-A2 | SYSTEMS AND METHODS FOR EVALUATING ENZYME COMPETENCY | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005105754-A1 | PYRAZOLE PHENYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245589-A1 | Pyrazole phenyl derivatives | HOFFMANN-LA ROCHE INC. | 2005-11-03 | — | — | US | disclosed |
| US-20050203160-A1 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-15 | — | — | US | disclosed |
| WO-2005085235-A1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| US-6921821-B2 | Antagonists of melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1175402-B1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORP (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1534703-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | ABBOTT LABORATORIES (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005030729-A1 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050059825-A1 | Novel process for the preparation of flecainide, its pharmaceutically acceptable salts and important intermediates thereof | APOTEX PHARMACHEM INC (CA) | 2005-03-17 | — | — | US | disclosed |
| US-20040220409-A1 | Flecainide synthesis | MCDANIEL WILLIAM C | 2004-11-04 | — | — | US | disclosed |
| US-6794492-B2 | N-(2,2,2-TRIFLUOROETHYL)GLYCINE DERIVATIVES; CAN BE USED TO PREPARE LIPOPHILIC PROTEINS ADAPTED FOR CROSSING THE BLOOD BRAIN BARRIER | CLEMSON UNIVERSITY | 2004-09-21 | — | — | US | disclosed |
| CN-1524527-A | Piperidine derivatives useful as CCR5 antagonists | ���鹫˾ | 2004-09-01 | — | — | CN | disclosed |
| US-6750214-B2 | PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | COLLIS ALAN JOHN (US) | 2004-06-15 | — | — | US | disclosed |
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| CN-1151131-C | Piperidine derivatives as CCR5 antagonists | ���鹫˾ | 2004-05-26 | — | — | CN | disclosed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| WO-2003106452-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-6642242-B2 | Antiproliferative agents to treat benign prostatic hyperplasia | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| US-6602885-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION | 2003-08-05 | — | — | US | disclosed |
| US-6593486-B2 | Reacting halobenzoic acid with 2,2,2-trifluoroethanol; thenhaloacetonitrile | PAR PHARMACEUTICAL, INC. | 2003-07-15 | — | — | US | disclosed |
| US-20030004185-A1 | Piperidine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2003-01-02 | — | — | US | disclosed |
| US-20020133013-A1 | Process for making cyanomethyl ester precursors of flecainide | FINETECH LTD. | 2002-09-19 | — | — | US | disclosed |
| WO-2002066413-A1 | FLECAINIDE SYNTHESIS | NARCHEM CORPORATION (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| CN-1349504-A | Piperidine derivatives as CCR5 antagonists | SCHERING CORP (US) | 2002-05-15 | — | — | CN | disclosed |
| US-6387930-B1 | ANTIARTHRITIC AGENTS; ANTIALLERGENS; SKIN DISORDERS; INFLAMMATORY BOWEL DISORDERS | SCHERING CORPORATION | 2002-05-14 | — | — | US | disclosed |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
| EP-1175402-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| US-20010046960-A1 | Novel perfluoroalkyl compounds and their methods of use and manufacture | CLEMSON UNIVERSITY | 2001-11-29 | — | — | US | disclosed |
| US-6316627-B1 | REACTING A HALOBENZOIC ACID OR ITS SALT WITH WITH 2,2,2-TRIFLUOROETHANOL IN THE PRESENCE OF A STRONG BASE AND COPPER OR A COPPER COMPOUND OR ALLOY, IF DESIRED FOLLOWED BY ACIDIFICATION; CONVERTING TO FLECAINIDE OR ITS SALT | FINE TECH LTD. (IL) | 2001-11-13 | — | — | US | disclosed |
| US-6306570-B1 | Silver halide light sensitive emulsion layer having enhanced photographic sensitivity | EASTMAN KODAK COMPANY | 2001-10-23 | — | — | US | disclosed |
| US-6288271-B1 | HALOBENZOIC ACID OR SALT WITH 2,2,2-TRIFLUOROETHANOL IN ESTERIFICATION REACTION IN THE PRESENCE OF STRONG BASE | FINETECH, LTD (IL) | 2001-09-11 | — | — | US | disclosed |
| US-6262078-B1 | Phenoxymethyl piperidine derivatives for the treatment of neuropathic pain | SYNTEX (U.S.A.) LLC | 2001-07-17 | — | — | US | disclosed |
| US-6153371-A | CONTAINING A CHROMOPHORE | EASTMAN KODAK COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
| WO-2000066559-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| US-6110937-A | A SODIUM CHANNEL BLOCKER TREATING AS LOCAL ANESTHETICS AND IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | SYNTEX USA, INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
| EP-1000060-A1 | NOVEL COMPOUNDS | AstraZeneca UK Limited (GB) | 2000-05-17 | — | — | EP | disclosed |
| US-6054260-A | Silver halide light sensitive emulsion layer having enhanced photographic sensitivity | EASTMAN KODAK COMPANY (US) | 2000-04-25 | — | — | US | disclosed |
| US-6001981-A | INSECTICIDES AND MITICIDES | DOW AGROSCIENCES LLC (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0741730-B1 | 1-SUBSTITUTED-4-FLUORO-1,4-DIAZONIABICYCLO 2.2.2]OCTANE SALTS AND THEIR APPLICATION AS FLUORINATING AGENTS | ALLIED SIGNAL INC (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999002528-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1999-01-21 | — | — | WO | disclosed |
| EP-0877734-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-11-18 | — | — | EP | disclosed |
| EP-0646575-B1 | Process for preparing fluorocarbon fluoroalkanesulfonates | MINNESOTA MINING & MFG (US) | 1998-11-04 | — | — | EP | disclosed |
| EP-0869119-A1 | Phenoxymethyl piperidine derivatives being sodium channle blockers | F. HOFFMANN-LA ROCHE AG (CH) | 1998-10-07 | — | — | EP | disclosed |
| CN-1194977-A | Phenoxymethyl piperidine derivatives | HOFFMANN LA ROCHE (CH) | 1998-10-07 | — | — | CN | disclosed |
| EP-0837870-A1 | SYNTHETIC MODIFICATION TO SPINOSYN COMPOUNDS | DOWELANCO (US) | 1998-04-29 | — | — | EP | disclosed |
| WO-1997023462-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-07-03 | — | — | WO | disclosed |
| US-5606084-A | Process of fluorinating organic compounds with 1-substituted-4-fluoro-1,4-diazoniabicyclo octane salts | ALLIEDSIGNAL INC. (US) | 1997-02-25 | — | — | US | disclosed |
| WO-1997000265-A1 | SYNTHETIC MODIFICATION TO SPINOSYN COMPOUNDS | DOWELANCO (US) | 1997-01-03 | — | — | WO | disclosed |
| EP-0741730-A1 | 1-SUBSTITUTED-4-FLUORO-1,4-DIAZONIABICYCLO 2.2.2]OCTANE SALTS AND THEIR APPLICATION AS FLUORINATING AGENTS | AlliedSignal Inc. (US) | 1996-11-13 | — | — | EP | disclosed |
| US-5550273-A | Process for preparing fluorocarbon fluoroalkanesulfonates | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| US-5459267-A | 1-substituted-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane salts and their application as fluorinating agents | ALLIEDSIGNAL INC. (US) | 1995-10-17 | — | — | US | disclosed |
| WO-1995017404-A1 | 1-SUBSTITUTED-4-FLUORO-1,4-DIAZONIABICYCLO[2.2.2]OCTANE SALTS AND THEIR APPLICATION AS FLUORINATING AGENTS | ALLIEDSIGNAL, INC. (US) | 1995-06-29 | — | — | WO | disclosed |
| EP-0646575-A1 | Process for preparing fluorocarbon fluoroalkanesulfonates | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-04-05 | — | — | EP | disclosed |
| EP-0136721-B1 | Carboxyalkenamidocephalosporins | SHIONOGI & CO (JP) | 1993-12-29 | — | — | EP | disclosed |
| US-5144029-A | Calcium antagonist | DELALANDE S.A. (FR) | 1992-09-01 | — | — | US | disclosed |
| US-5017572-A | CALCIUM ANTAGONIST | DELALANDE S.A. (FR) | 1991-05-21 | — | — | US | disclosed |
| US-4912224-A | Containing a aminothiazolyl or aminothiadiazolyl ring | SHIONOGI & CO., LTD. (JP) | 1990-03-27 | — | — | US | disclosed |
| US-4748170-A | Carboxyalkenamidocephalosporins | SHIONOGI & CO., LTD. (JP) | 1988-05-31 | — | — | US | disclosed |
| US-4634697-A | Carboxyalkenamidocephalosporins | SHIONOGI & CO., LTD. (JP) | 1987-01-06 | — | — | US | disclosed |
| EP-0136721-A2 | Carboxyalkenamidocephalosporins | SHIONOGI & CO., LTD. (JP) | 1985-04-10 | — | — | EP | disclosed |
| EP-0116495-A1 | Androstene-17-dithioketals | E.R. Squibb & Sons, Inc. (US) | 1984-08-22 | — | — | EP | disclosed |
| US-4427592-A | Androstene-17-dithioketals | E. R. SQUIBB & SONS, INC. (US) | 1984-01-24 | — | — | US | disclosed |
| US-4427592-A | Androstene-17-dithioketals | E. R. SQUIBB & SONS, INC. (US) | 1984-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228446-A1 | PREPARATION METHOD FOR BICYCLIC COMPOUND AND APPLICATION AS ANTIFUNGAL AGENT | ERG28, CYP51A1, DPM1 | CA1 3084/4885CA2 1335/4885CA9 763/4885 |
| US-20140163015-A1 | HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS | TBXA2R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR3D | CA1 2701/4885CA2 1236/4885CA9 3209/4885 |
| US-20140051656-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CA1 4745/4885CA2 4564/4885CA9 3805/4885 |
| US-20130012488-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3R2 | CA1 2871/4885CA2 3529/4885CA9 3155/4885 |
| US-20130345181-A1 | PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS | BUB1B, BUB1, PPM1D | CA1 4249/4885CA2 3427/4885CA9 3928/4885 |
| US-10131649-B2 | Bicyclic compounds as pest control agents | DDT, BCHE, BAK1 | CA1 2938/4885CA2 3307/4885CA9 3797/4885 |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | CA1 1117/4885CA2 1842/4885CA9 819/4885 |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | PIK3CA, DPYD, CDK2 | CA1 4843/4885CA2 4261/4885CA9 4584/4885 |
| US-20050059825-A1 | Novel process for the preparation of flecainide, its pharmaceutically acceptable salts and important intermediates thereof | SCN2B, CYP2C9, HCN4 | CA1 820/4885CA2 154/4885CA9 346/4885 |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CA1 4745/4885CA2 4564/4885CA9 3805/4885 |
| US-20110313001-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MAPT, BACE1, APP | CA1 149/4885CA2 1012/4885CA9 1662/4885 |
| US-20130029978-A1 | NOVEL ARYL UREA DERIVATIVE | FAAH, FAAH2, NAT1 | CA1 4015/4885CA2 3527/4885CA9 3878/4885 |
| US-11498921-B1 | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | EGFR, WEE1, DPYD | CA1 4447/4885CA2 3821/4885CA9 2367/4885 |
| US-20100035953-A1 | Pyrazole Phenyl Derivatives | PPARD, PPARG, PPARA | CA1 4862/4885CA2 4613/4885CA9 4722/4885 |
| US-20130196984-A1 | 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | CA1 410/4885CA2 478/4885CA9 1185/4885 |
| US-11731966-B2 | Compounds and their methods of use | SCN1A, SCN3A, SCN1B | CA1 285/4885CA2 213/4885CA9 1572/4885 |
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | CDC7, CDK7, CDK17 | CA1 2588/4885CA2 1775/4885CA9 3593/4885 |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CA1 4745/4885CA2 4564/4885CA9 3805/4885 |
| US-20140323474-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | TBXA2R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR3D | CA1 2701/4885CA2 1236/4885CA9 3209/4885 |
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | CA1 4717/4885CA2 3789/4885CA9 3956/4885 |
| US-20040220409-A1 | Flecainide synthesis | KCNH1, CYP3A43, CYP2F1 | CA1 605/4885CA2 390/4885CA9 700/4885 |
| US-20250059180-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CYP2C9, CYP1B1, SULT1A1 | CA1 1056/4885CA2 277/4885CA9 309/4885 |
| US-20010046960-A1 | Novel perfluoroalkyl compounds and their methods of use and manufacture | PFAS, PTMS, QRFPR | CA1 2482/4885CA2 4544/4885CA9 3297/4885 |
| US-20110076291-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | CA1 1258/4885CA2 1810/4885CA9 1564/4885 |
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | CA1 3434/4885CA2 2611/4885CA9 3671/4885 |
| US-12622917-B2 | High-activity Wnt pathway inhibitor compound | WNT1, WNT3, WNT3A | CA1 385/4885CA2 704/4885CA9 132/4885 |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | RET, TK1, DSTYK | CA1 4584/4885CA2 3015/4885CA9 2765/4885 |
| US-20080103133-A1 | 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[b][1,4]DIAZEPINE DERIVATIVES | BACE1, BACE2, PSEN1 | CA1 566/4885CA2 1353/4885CA9 2316/4885 |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | CA1 1117/4885CA2 1842/4885CA9 819/4885 |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CA1 4745/4885CA2 4564/4885CA9 3805/4885 |
| US-20190297887-A1 | BICYCLIC COMPOUNDS AS PESTICIDES | DDT, BCHE, ACHE | CA1 822/4885CA2 1591/4885CA9 2849/4885 |
| US-20100222320-A1 | TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | BACE1, PSEN1, PSEN2 | CA1 1151/4885CA2 3556/4885CA9 4333/4885 |
| US-20050245589-A1 | Pyrazole phenyl derivatives | PPARD, PPARG, PPARA | CA1 4862/4885CA2 4613/4885CA9 4722/4885 |
| US-20230312504-A1 | QUINOLINE COMPOUNDS | NQO2, ABCG2, NQO1 | CA1 4627/4885CA2 2698/4885CA9 3494/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | CA1 4701/4885CA2 3728/4885CA9 4109/4885 |
| US-20210355118-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CA1 285/4885CA2 213/4885CA9 1572/4885 |
| US-20230019236-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | CA1 4547/4885CA2 2713/4885CA9 3742/4885 |
| US-20140349997-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | CA1 4701/4885CA2 3728/4885CA9 4109/4885 |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | CA1 2514/4885CA2 959/4885CA9 1762/4885 |
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | CA1 4575/4885CA2 3992/4885CA9 4179/4885 |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | CA1 452/4885CA2 376/4885CA9 972/4885 |
| US-20200095260-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | CA1 1934/4885CA2 4637/4885CA9 3684/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CA1 4745/4885CA2 4564/4885CA9 3805/4885 |
| US-12552796-B2 | EED inhibitor, and preparation method therefor and use thereof | HSD11B1, CYP4A11, CYP8B1 | CA1 389/4885CA2 822/4885CA9 495/4885 |
| US-20220226326-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | CA1 4701/4885CA2 3728/4885CA9 4109/4885 |
| US-20020133013-A1 | Process for making cyanomethyl ester precursors of flecainide | CA2, KCNH1, SCN1B | CA1 47/4885CA2 1/4885CA9 41/4885 |
| US-10954202-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PTPN1, PTPN2, PTPN18 | CA1 4547/4885CA2 2713/4885CA9 3742/4885 |
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | CA1 4723/4885CA2 4640/4885CA9 4319/4885 |
| US-10106541-B2 | Intermediates for preparing CGRP receptor antagonists | CALCR, CALCRL, VIPR1 | CA1 3085/4885CA2 1889/4885CA9 3077/4885 |
| US-20140057938-A1 | KAT ll INHIBITORS | KAT2A, KAT7, KAT5 | CA1 3964/4885CA2 4793/4885CA9 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.